Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

Functional Dyspepsia Clinical Trial

Official title:

Randomized Multicentre Open-label Study to Investigate the Non-inferiority of Itopride Hydrochloride 150mg Once Daily Versus Itopride Hydrochloride 50 mg Thrice Daily in Subjects With Functional (Non-ulcer) Dyspepsia or Chronic Gastritis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06217393
• Other study ID #: ITOP-322-0216
• Status: Recruiting
• Phase: Phase 3
• Start date: February 28, 2024
• Est. completion date: February 28, 2025

Study information

• Verified date: April 2024
• Source: Abbott
• Contact: Suntje Sander
• Phone: '+49 (0) 511 6750 3254
• Email: suntje.sander[@]abbott.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to:

• assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar effect on gastrointestinal symptoms caused by gastric dysmotility and delayed gastric emptying, like bloating sensation, early satiety, postprandial fullness, upper abdominal pain or discomfort, anorexia, heartburn, nausea and vomiting in functional (non-ulcer) dyspepsia or chronic gastritis, as Itopride Hydrochloride 50 mg film coated tablets administered thrice a day.

• investigate assessment of the treatment provided to each participant.

• monitor safety and tolerability of Itopride Hydrochloride 150 mg extended release tablets, taken once daily before one of the main meals (preferably same meal throughout the treatment) and Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals.

Description:

This is a muti-national study, in subjects with functional dyspepsia. The study will screen approximately 700 subjects and include 564 subjects (282 subjects in both arms Test and Active control arm) and the treatment will be given as follows.

• Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before any of the main meals (preferably same meal throughout the treatment) OR

• Active Control group - Itopride Hydrochloride 50 mg film coated tablets thrice daily before meals Total study participation will include screening for two weeks, treatment duration of eight weeks and follow-up for one week after the end of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 564
• Est. completion date: February 28, 2025
• Est. primary completion date: February 28, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Adult male and/or non-pregnant non-lactating female subjects aged above 18 years.

2. Subjects provided written informed consent and are willing to participate in the study.

3. Subjects with functional (non-ulcer) dyspepsia according to Rome IV criteria including postprandial distress syndrome (PDS) and with or without EPS (epigastric pain syndrome) with one or more of the following:

• bothersome postprandial fullness,

• bothersome early satiation

• bothersome epigastric pain,

• bothersome epigastric burning for at least 12 weeks in the preceding 6 months

4. No evidence of organic, systemic, metabolic or structural disease likely to explain symptoms - Subjects who have to undergone physical examination and lab tests (including white-cell and red-cell counts, measurement of fasting blood sugar and liver-function tests), abdominal ultrasonography, and upper GI endoscopy* in order to rule out structural cause for symptoms of FD.

*history of upper GI endoscopy within 6 months prior to enrolment or at screening.

5. Baseline severity of at least moderate symptoms on LDQ (total score = 9) at screening.

6. H. pylori negative documented test report within 3 months prior to enrolment or during screening.

Exclusion Criteria:

1. Known hypersensitivity to Itopride or any component of the formulation and to any other related drug.

2. Subject with history or presence of clinically relevant evidence of cardiovascular, neurological, gastrointestinal/hepatic, renal, psychiatric, respiratory, urogenital, hematologic/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/ connective tissue, musculoskeletal, metabolic/nutritional, drug hypersensitivity, allergy, endocrine, major surgery or other relevant disease as revealed by medical history requiring treatment which at investigator's discretion might interfere with the study.

3. Subjects who cannot be treated with Itopride in line with the prescribing information.

4. Subjects scheduled for surgery during the study.

5. Subjects with a history of difficulty in swallowing.

6. Subject requiring concomitant treatment with anticholinergic drugs, drugs with narrow therapeutic index, sustained release or enteric-coated formulations.

7. Subjects taking Acid release inhibitors (e.g. histamine-2-receptor [H2]- antagonists, proton pump inhibitors [PPI], or potassium-competitive acid blockers), antacids (e.g. aluminium- or magnesium hydroxide, sodium bicarbonate), gastric mucosa protectors (e.g. sucralfate, rebamipide).

8. Subject with history of unusual bleeding and family history for bleeding disorders.

9. Subjects with only reflux-related symptoms or who have predominantly reflux-related symptoms.

10. Subjects with esophagitis, Barrett's esophagus, erosions or peptic ulcer disease within one year prior to the study or Zollinger-Ellison Syndrome.

11. Dyspepsia that is exclusively relieved by defecation or associated with a change in stool frequency or stool form to exclude IBS.

12. Clinically significant ECG abnormalities.

13. Subjects treated with Itopride or any other gastroprokinetic within 4 weeks prior to screening.

14. Subjects who took non-steroidal anti-inflammatory drugs for more than 2 weeks prior to screening

15. Subjects with refractory FD1 (defined as FD presenting symptoms continuing for at least 6 months, unresponsive to at least two medical treatments such as PPIs, prokinetics, or H. pylori eradication) as per investigator's discretion

16. History of or known inflammatory bowel disease (IBD) or coeliac disease.

17. History of or known severe hepatic, renal, pancreatic, cardiac, metabolic, hematological or malignant disease or trimethylaminuria.

18. Subjects with changed smoking status within the last three months.

19. History of or known GI malignancy or ulcers associated to malignancy or any alarm features for GI malignancy, e.g. GI bleeding.

20. Subjects who do not meet the criteria stated in concomitant medication section.

21. Subjects with history of severe depression, anxiety or other psychological disorders.

22. Females with child-bearing potential must agree to use an acceptable method of contraception during the study.

23. Subjects in whom an increase in gastrointestinal motility could be harmful, e.g., (history of) gastrointestinal hemorrhage, mechanical obstruction or perforation.

24. Specific food intolerance which is relieved by diet modifications (e.g. lactose intolerance, celiac disease).

25. Subjects with confirmed IBS as per Rome IV criteria.

26. Current alcohol or drug abuse.

27. History of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings or vasectomies.

28. Hepatic cirrhosis or abnormal liver laboratory findings (defined as >3xULN of ALT or AST).

29. Subjects under hemodialysis therapy or having advanced chronic kidney disease (defined as eGFR <60 mL/min).

30. History of or known congestive heart failure NYHA class III and IV, or any other uncontrolled chronic diseases, such as: uncontrolled hypertension (systolic/diastolic blood pressure =160/100 mmHg); uncontrolled diabetes (HbA1c >8%).

31. Subjects currently being known to be afflicted by serious infection(s), or any known severe illness(es) which are judged by the investigator could interfere with subjects' safety and/or study evaluation.

Related Conditions & MeSH terms

• Dyspepsia
• Functional Dyspepsia

Intervention

Drug:
• Itopride Hydrochloride 150 mg extended release tablets
The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals
• Itopride Hydrochloride 50 mg film coated tablets
The intervention in the study is in form of test and active control groups- see details below • Test group - Itopride Hydrochloride 150 mg extended release tablets once daily before one of the main meals (preferably the same meal throughout the treatment) • Active Control group - Itopride Hydrochloride 50 mg film coated tablets 3 times daily before meals

Locations

Country	Name	City	State
Armenia	"Grigor Narekatsi" MC, CJSC	Yerevan
Armenia	"Hera Med" LLC ("Medicus" Medical Center)	Yerevan
Armenia	"Institute of Surgery Mickaelyan" CJSC	Yerevan
Armenia	Polyclinic N 12 Health State, CJSC	Yerevan
Malaysia	Hospital Sultanah Bahiyah	Alor Setar
Malaysia	Queen Elizabeth Hospital	Kota Kinabalu
Malaysia	Pantai Hospital Kuala Lumpur	Kuala Lumpur
Malaysia	UMMC	Petaling Jaya

Sponsors (1)

Lead Sponsor	Collaborator
Abbott

Countries where clinical trial is conducted

Armenia,  Malaysia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Treatment acceptance by subjects using 5-point Likert scale at the end of the treatment; (1. Not at all satisfied, 2. Slightly satisfied, 3. Neutral, 4. Very satisfied, 5. Extremely satisfied.)	Treatment acceptance and ease of use assessed by subjects using 5-point Likert scale	8 weeks
Other	To evaluate safety and tolerability in both treatment arms	To evaluate the safety and tolerability of the two treatments by assessing the following safety endpoints: Treatment emergent adverse events (TEAEs) as detected by physical examination, laboratory assessments and vital signs. For each unique treatment, treatment emergent AEs will be summarized per primary standard of care, per Highest Level Term by primary Standard of care and per preferred term by highest level term and primary standard of care.	8 weeks
Primary	To assess the comparable efficacy of Itopride Hydrochloride 150 mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 8 weeks' treatment	Change in the overall severity of functional dyspepsia between baseline and week 8, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score	8 weeks
Secondary	To assess the comparable efficacy of Itopride Hydrochloride 150mg extended release tablet (administered once daily) and Itopride Hydrochloride 50 mg film coated tablets (administered TID) after 4 weeks treatment.	Change in the overall severity of functional dyspepsia between baseline and week 4, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score	4 weeks
Secondary	To assess quality of life for the two treatment arms using Disease Specific Quality of Life (Short Form - Nepean Dyspepsia Index SF-NDI) at baseline and end of treatment	Disease Specific Quality of Life (Nepean Dyspepsia Index NDI) assessed at baseline and week 8	8 weeks
Secondary	Assess the symptomatology (sensation of bloating, early satiety, abdominal pain or discomfort, epigastric pain, epigastric burning, anorexia, heartburn, nausea and vomiting) of the disease in both treatment arms after 4 and 8 weeks of treatment.	Change from baseline of NRS 11 score for symptoms (sensation of bloating, early satiety, postprandial fullness, upper abdominal pain or discomfort (epigastric pain, epigastric burning), anorexia (loss of appetite), heartburn, nausea and vomiting) after 4 and 8 weeks of treatment	8 weeks
Secondary	Change in the overall severity of functional dyspepsia between baseline and week 4, as measured by the Leeds Dyspepsia Questionnaire (LDQ) severity score (range 0-40), where 0 is symptom free and 40 is severe dyspepsia	Responder analysis for adequate/satisfactory relief as assessed by LDQ and/or NRS 11	8 weeks